SG11201609403UA - Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases - Google Patents

Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases

Info

Publication number: SG11201609403UA
Authority: SG; Singapore
Prior art keywords: tgr5; fxr; prevention; treatment; mediated diseases
Prior art date: 2014-05-29

Application number

SG11201609403UA

Inventor

Angela Zampella

Original Assignee

Bar Pharmaceuticals S R L

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-29

Filing date

2015-05-28

Publication date

2016-12-29

2015-05-28 Application filed by Bar Pharmaceuticals S R L filed Critical Bar Pharmaceuticals S R L

2016-12-29 Publication of SG11201609403UA publication Critical patent/SG11201609403UA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Virology (AREA)
Toxicology (AREA)
Oncology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)

SG11201609403UA 2014-05-29 2015-05-28 Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases SG11201609403UA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ITFI20140130		2014-05-29
PCT/EP2015/061802 WO2015181275A1 (en)	2014-05-29	2015-05-28	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases

Publications (1)

Publication Number	Publication Date
SG11201609403UA true SG11201609403UA (en)	2016-12-29

Family

ID=51454763

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201609403UA SG11201609403UA (en)	2014-05-29	2015-05-28	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
SG10201809362RA SG10201809362RA (en)	2014-05-29	2015-05-28	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201809362RA SG10201809362RA (en)	2014-05-29	2015-05-28	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases

Country Status (25)

Country	Link
US (2)	US10407462B2 (en)
EP (2)	EP3149019B1 (en)
JP (1)	JP6820253B2 (en)
KR (1)	KR102491556B1 (en)
CN (2)	CN106661079B (en)
AU (1)	AU2015265893B2 (en)
CA (1)	CA2948585C (en)
CY (1)	CY1122631T1 (en)
DK (2)	DK3149019T3 (en)
EA (1)	EA032820B1 (en)
ES (2)	ES2768718T3 (en)
FI (1)	FI3626725T3 (en)
HR (2)	HRP20230170T1 (en)
HU (2)	HUE061506T2 (en)
LT (2)	LT3626725T (en)
MA (1)	MA39881B1 (en)
MX (2)	MX2020004024A (en)
PH (1)	PH12016502327A1 (en)
PL (2)	PL3149019T3 (en)
PT (2)	PT3149019T (en)
RS (2)	RS64050B1 (en)
SG (2)	SG11201609403UA (en)
SI (2)	SI3626725T1 (en)
SM (2)	SMT202300057T1 (en)
WO (1)	WO2015181275A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2545964A1 (en)	2011-07-13	2013-01-16	Phenex Pharmaceuticals AG	Novel FXR (NR1H4) binding and activity modulating compounds
LT3626725T (en)	2014-05-29	2023-03-10	Bar Pharmaceuticals S.R.L.	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
WO2016045480A1 (en) *	2014-09-28	2016-03-31	上海源力生物技术有限公司	Method for preparing obeticholic acid
KR20170094184A (en)	2014-11-06	2017-08-17	이난타 파마슈티칼스, 인코포레이티드	Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
CN111944006B (en) *	2014-11-17	2021-12-17	正大天晴药业集团股份有限公司	New 7-keto-6 beta-alkyl cholanic acid derivative in preparation of obeticholic acid and application thereof in medical field
JP6724004B2 (en)	2014-11-19	2020-07-15	エヌゼットピーユーケーリミテッド	5β-6-Alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroid FXR modulators
MX381239B (en)	2014-11-19	2025-03-12	Nzp Uk Ltd	6.ALPHA-ALKYL-6,7-DIONE STEROIDS AS INTERMEDIATE FOR THE PRODUCTION OF STEROID MODULATORS OF THE FARNESOID X RECEPTOR (FXR).
CA2968305A1 (en)	2014-11-19	2016-05-26	NZP UK Limited	6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
BR112017010319B1 (en)	2014-11-19	2023-04-11	NZP UK Limited	6-ALKYL-7-HYDROXY-4-EN-3-ONE STEROIDS AND PROCESS FOR PREPARING THEM
US10208081B2 (en)	2014-11-26	2019-02-19	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US11578097B2 (en)	2014-11-26	2023-02-14	Enanta Pharmaceuticals, Inc.	Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
MX2017006833A (en)	2014-11-26	2018-02-13	Enanta Pharm Inc	Bile acid analogs as fxr/tgr5 agonists and methods of use thereof.
SG11201706089RA (en)	2015-02-11	2017-09-28	Enanta Pharm Inc	Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
SMT202100593T1 (en)	2015-03-31	2021-11-12	Enanta Pharm Inc	Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
DK3310801T3 (en)	2015-06-19	2021-06-21	Intercept Pharmaceuticals Inc	TGR5 MODULATORS AND METHODS FOR USING IT
WO2017053826A1 (en) *	2015-09-24	2017-03-30	Intercept Pharmaceuticals, Inc.	Methods and intermediates for the preparation bile acid derivatives
WO2017147174A1 (en) *	2016-02-23	2017-08-31	Enanta Pharmaceuticals, Inc.	Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2017147159A1 (en) *	2016-02-23	2017-08-31	Enanta Pharmaceuticals, Inc.	Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en)	2016-02-23	2019-06-18	Enanta Pharmaceuticals, Inc.	Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
EA038632B1 (en) *	2016-03-11	2021-09-27	Интерсепт Фармасьютикалз, Инк.	7,11-dihydroxy-6-ethyl-5-cholan-24-oic acid and pharmaceutical compositions thereof for treating or preventing a disease or condition mediated by the farnesoid x receptor (fxr)
CN105859817A (en) *	2016-05-09	2016-08-17	成都宇西医药技术有限公司	Method for preparing 3 alpha-hydroxy-6-vinyl-7-ketone-5 beta-ursodeoxycholic acid
GB201608777D0 (en)	2016-05-18	2016-06-29	Dextra Lab Ltd	Compounds
WO2017207648A1 (en)	2016-05-31	2017-12-07	Bionice, S.L.U	Process and intermediates for the preparation of obeticholic acid and derivatives thereof
EP3464316A4 (en)	2016-06-01	2020-02-19	Dr. Reddy's Laboratories Ltd.	Process for preparation of obeticholic acid
CA2968836A1 (en)	2016-06-13	2017-12-13	Gilead Sciences, Inc.	Fxr (nr1h4) modulating compounds
MX2018015443A (en)	2016-06-13	2019-04-11	Gilead Sciences Inc	Fxr (nr1h4) modulating compounds.
IT201600068742A1 (en) *	2016-07-01	2018-01-01	Bar Pharmaceuticals Soc A Responsabilita Limitata	DERIVATIVES OF IODESEXICOLIC ACID AND THEIR USE
CA3045023A1 (en)	2016-11-29	2018-06-07	Enanta Pharmaceuticals, Inc.	Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en)	2017-02-14	2018-08-23	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as fxr agonists and methods of use thereof
AU2018243719B2 (en)	2017-03-28	2021-01-21	Gilead Sciences, Inc.	Therapeutic combinations for treating liver diseases
AU2018249950B2 (en) *	2017-04-07	2023-09-21	Enanta Pharmaceuticals, Inc.	Process for preparation of sulfonyl carbamate bile acid derivatives
CN109021054B (en) *	2017-06-09	2021-04-09	博瑞生物医药（苏州）股份有限公司	FXR agonist
CN109021055B (en) *	2017-06-09	2021-04-09	博瑞生物医药（苏州）股份有限公司	FXR agonists
CN109021056B (en) *	2017-06-09	2021-03-09	博瑞生物医药（苏州）股份有限公司	Farnesoid X receptor agonists
EP3660030A4 (en) *	2017-07-26	2021-04-21	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Method for preparing steroid derivative fxr agonist
WO2019085963A1 (en) *	2017-11-02	2019-05-09	正大天晴药业集团股份有限公司	Method for preparing cholic acid compound
CA3124702A1 (en)	2019-01-15	2020-07-23	Gilead Sciences, Inc.	Fxr (nr1h4) modulating compounds
CA3233305A1 (en)	2019-02-19	2020-08-27	Gilead Sciences, Inc.	Solid forms of fxr agonists
WO2021071837A1 (en)	2019-10-07	2021-04-15	Kallyope, Inc.	Gpr119 agonists
CN112824425B (en) *	2019-11-21	2023-10-03	成都西岭源药业有限公司	6-alkenyl substituted cholic acid compound and preparation method and application thereof
JP2023516187A (en)	2020-02-28	2023-04-18	キャリーオペ，インク．	GPR40 agonist
IT202000008515A1 (en)	2020-04-21	2021-10-21	Bar Pharmaceuticals Soc A Responsabilita Limitata	METHOD FOR THE SYNTHESIS OF A COLAN DERIVATIVE
AU2021275038A1 (en)	2020-05-19	2022-12-22	Kallyope, Inc.	AMPK activators
JP2023531726A (en)	2020-06-26	2023-07-25	キャリーオペ，インク．	AMPK Activator
IT202200011705A1 (en) *	2022-06-01	2023-12-01	Prec Bio Therapeutics S R L	CHOLESTEROL DERIVATIVES AND THEIR USES
WO2024006537A1 (en) *	2022-07-01	2024-01-04	Intercept Pharmaceuticals, Inc.	Methods for ameliorating cognitive impairment using bile acid derivatives
IT202200018669A1 (en)	2022-09-13	2024-03-13	Bar Pharmaceuticals Soc A Responsabilita Limitata	PHARMACEUTICAL COMBINATIONS INCLUDING CHOLANE DERIVATIVES AND THEIR USES
WO2024097247A1 (en) *	2022-10-31	2024-05-10	Intercept Pharmaceuticals, Inc.	Uses of farnesoid x receptor agonists
WO2024195903A1 (en) *	2023-03-21	2024-09-26	경희대학교 산학협력단	Novel cholic acid derivative and use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2356887A1 (en) *	1998-12-23	2000-06-29	Glaxo Group Limited	Assays for ligands for nuclear receptors
IL157816A0 (en) *	2001-03-12	2004-03-28	Roberto Pellicciari	Steroids as agonists for fxr
EP1568706A1 (en) *	2004-02-26	2005-08-31	Intercept Pharmaceuticals, Inc.	Novel steroid agonist for FXR
PT1734970E (en) *	2004-03-12	2015-03-11	Intercept Pharmaceuticals Inc	Treatment of fibrosis using fxr ligands
ITMI20050912A1 (en)	2005-05-19	2006-11-20	Erregierre Spa	PROCESS OF PREPARATION OF ACIDS 3-A-YA (B) -DIDROSSI-6-A (B) -ALCHIL-5B-COLANICI
US7932244B2 (en)	2006-06-27	2011-04-26	Intercept Pharmaceuticals, Inc.	Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
US8940719B2 (en) *	2006-07-03	2015-01-27	Academia Sinica	Lithocholic acid analogues that inhibit sialyltransferase
FR2908310B1 (en) *	2006-11-14	2009-07-10	Phytodia	AGONIST PRODUCTS OF TGR5 AND THEIR APPLICATIONS
EA017714B1 (en) *	2007-01-19	2013-02-28	Интерсепт Фармасьютикалз, Инк.	Tgr5 modulators and methods of use thereof
EP1947108A1 (en) *	2007-01-19	2008-07-23	Intercept Pharmaceuticals, Inc.	TGR5 modulators and methods of use thereof
EA020310B1 (en)	2008-07-30	2014-10-30	Интерсепт Фармасьютикалз, Инк.	Tgr5 modulators and use thereof
AU2009316566B9 (en) *	2008-11-19	2014-05-15	Intercept Pharmaceuticals, Inc.	TGR5 modulators and method of use thereof
EP3150620B1 (en) *	2008-11-19	2020-01-08	Intercept Pharmaceuticals, Inc.	Tgr5 modulators and methods of use thereof
WO2011150286A2 (en)	2010-05-26	2011-12-01	Satiogen Pharmaceuticals,Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2012047495A2 (en) *	2010-09-27	2012-04-12	Kythera Biopharmaceuticals, Inc.	Methods for preparing synthetic bile acids and compositions comprising the same
CA2842707A1 (en)	2011-08-04	2013-02-07	Lumena Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of pancreatitis
KR20190121871A (en) *	2012-06-19	2019-10-28	인터셉트 파마슈티컬즈, 인크.	Preparation, uses and solid forms of obeticholic acid
EP2912013B1 (en) *	2012-10-26	2017-10-11	Intercept Pharmaceuticals, Inc.	Process for preparing bile acid derivatives
US20140206657A1 (en) *	2013-01-18	2014-07-24	City Of Hope	Bile acid analog tgr5 agonists
CN103143021A (en) *	2013-03-21	2013-06-12	中国药科大学	Application of PPAR alpha-UGT (peroxisome proliferator activated receptor alpha-uridine diphosphate glucuronosyl transferase) pathway inhibitor in treating inflammatory bowel diseases
CN108245523B (en) *	2013-05-14	2021-03-26	英特塞普特医药品公司	11-hydroxy derivatives of bile acids and amino acid conjugates thereof as farnesoid X receptor modulators
CN110437297B9 (en) *	2013-08-01	2022-01-11	美国卫生和人力服务部	Inhibitors of farnesoid X receptor and use in medicine
US10166246B2 (en) *	2014-05-27	2019-01-01	City Of Hope	TGR5 agonist complexes for treating diabetes and cancer
LT3626725T (en)	2014-05-29	2023-03-10	Bar Pharmaceuticals S.R.L.	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
US20170233431A1 (en) *	2016-02-17	2017-08-17	City Of Hope	Bile acid derivatives and methods for synthesis and use

2015
- 2015-05-28 LT LTEP19204247.1T patent/LT3626725T/en unknown
- 2015-05-28 MX MX2020004024A patent/MX2020004024A/en unknown
- 2015-05-28 EP EP15731260.4A patent/EP3149019B1/en active Active
- 2015-05-28 WO PCT/EP2015/061802 patent/WO2015181275A1/en active Application Filing
- 2015-05-28 MX MX2016015724A patent/MX373721B/en active IP Right Grant
- 2015-05-28 HU HUE19204247A patent/HUE061506T2/en unknown
- 2015-05-28 PT PT157312604T patent/PT3149019T/en unknown
- 2015-05-28 HU HUE15731260A patent/HUE048351T2/en unknown
- 2015-05-28 SM SM20230057T patent/SMT202300057T1/en unknown
- 2015-05-28 CN CN201580028528.2A patent/CN106661079B/en active Active
- 2015-05-28 DK DK15731260.4T patent/DK3149019T3/en active
- 2015-05-28 PL PL15731260T patent/PL3149019T3/en unknown
- 2015-05-28 LT LTEP15731260.4T patent/LT3149019T/en unknown
- 2015-05-28 PT PT192042471T patent/PT3626725T/en unknown
- 2015-05-28 HR HRP20230170TT patent/HRP20230170T1/en unknown
- 2015-05-28 SG SG11201609403UA patent/SG11201609403UA/en unknown
- 2015-05-28 SI SI201531924T patent/SI3626725T1/en unknown
- 2015-05-28 PL PL19204247.1T patent/PL3626725T3/en unknown
- 2015-05-28 EA EA201692316A patent/EA032820B1/en unknown
- 2015-05-28 RS RS20230132A patent/RS64050B1/en unknown
- 2015-05-28 ES ES15731260T patent/ES2768718T3/en active Active
- 2015-05-28 SM SM20200070T patent/SMT202000070T1/en unknown
- 2015-05-28 CN CN201910107511.6A patent/CN110003301B/en active Active
- 2015-05-28 CA CA2948585A patent/CA2948585C/en active Active
- 2015-05-28 SG SG10201809362RA patent/SG10201809362RA/en unknown
- 2015-05-28 DK DK19204247.1T patent/DK3626725T3/en active
- 2015-05-28 RS RS20200163A patent/RS59910B1/en unknown
- 2015-05-28 ES ES19204247T patent/ES2938874T3/en active Active
- 2015-05-28 US US15/314,771 patent/US10407462B2/en active Active
- 2015-05-28 AU AU2015265893A patent/AU2015265893B2/en active Active
- 2015-05-28 SI SI201531091T patent/SI3149019T1/en unknown
- 2015-05-28 FI FIEP19204247.1T patent/FI3626725T3/en active
- 2015-05-28 MA MA39881A patent/MA39881B1/en unknown
- 2015-05-28 JP JP2017514960A patent/JP6820253B2/en active Active
- 2015-05-28 KR KR1020167034084A patent/KR102491556B1/en active Active
- 2015-05-28 EP EP19204247.1A patent/EP3626725B1/en active Active
2016
- 2016-11-22 PH PH12016502327A patent/PH12016502327A1/en unknown
2019
- 2019-08-01 US US16/529,571 patent/US11117926B2/en active Active
2020
- 2020-02-11 HR HRP20200225TT patent/HRP20200225T1/en unknown
- 2020-02-12 CY CY20201100131T patent/CY1122631T1/en unknown

Also Published As

Publication number	Publication date
ES2768718T3 (en)	2020-06-23
CA2948585C (en)	2022-07-26
KR102491556B1 (en)	2023-01-25
JP2017516856A (en)	2017-06-22
BR112016028085A2 (en)	2017-08-22
US20170190731A1 (en)	2017-07-06
CY1122631T1 (en)	2021-03-12
HRP20200225T1 (en)	2020-05-29
DK3626725T3 (en)	2023-02-27
JP6820253B2 (en)	2021-01-27
US11117926B2 (en)	2021-09-14
CN106661079A (en)	2017-05-10
RS64050B1 (en)	2023-04-28
KR20170008767A (en)	2017-01-24
CN110003301B (en)	2022-06-10
LT3626725T (en)	2023-03-10
MA39881B1 (en)	2020-02-28
CN110003301A (en)	2019-07-12
PT3626725T (en)	2023-02-23
SMT202000070T1 (en)	2020-03-13
PT3149019T (en)	2020-02-19
AU2015265893A1 (en)	2016-12-08
WO2015181275A8 (en)	2016-02-18
MX373721B (en)	2025-03-04
SMT202300057T1 (en)	2023-03-17
EP3149019A1 (en)	2017-04-05
HUE061506T2 (en)	2023-07-28
SI3149019T1 (en)	2020-03-31
DK3149019T3 (en)	2020-02-17
EP3626725B1 (en)	2022-11-30
MX2020004024A (en)	2021-12-10
LT3149019T (en)	2020-02-25
CA2948585A1 (en)	2015-12-03
PH12016502327A1 (en)	2017-02-06
HUE048351T2 (en)	2020-07-28
US20190352328A1 (en)	2019-11-21
PL3626725T3 (en)	2023-04-03
WO2015181275A1 (en)	2015-12-03
EP3626725A1 (en)	2020-03-25
EA032820B1 (en)	2019-07-31
SI3626725T1 (en)	2023-04-28
EA201692316A1 (en)	2017-03-31
US10407462B2 (en)	2019-09-10
RS59910B1 (en)	2020-03-31
SG10201809362RA (en)	2018-11-29
FI3626725T3 (en)	2023-03-16
EP3149019B1 (en)	2019-12-04
HRP20230170T1 (en)	2023-03-31
CN106661079B (en)	2019-03-01
PL3149019T3 (en)	2020-07-27
MX2016015724A (en)	2017-07-11
ES2938874T3 (en)	2023-04-17
AU2015265893B2 (en)	2020-11-12

Publication	Publication Date	Title
SG11201609403UA (en)	2016-12-29	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
IL252596A0 (en)	2017-07-31	Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
IL247841A0 (en)	2016-11-30	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
IL250663A0 (en)	2017-04-30	Gamma-diketones for treatment and prevention of aging skin and wrinkles
HK1232120A1 (en)	2018-01-05	Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same
HRP20180260T1 (en)	2018-03-09	Buprenorphine dimer and its use in treatment of gastrointestinal disorders
RS65173B1 (en)	2024-03-29	Composition for the prevention and/or treatment of allergy symptoms
IL251135A (en)	2017-12-31	Method for the synthesis of hydroxy-triglycerides and use thereof for the prevention and treatment of diseases
IL248381A0 (en)	2016-11-30	Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
EP3223828A4 (en)	2018-06-27	Methods for the treatment and prevention of asbestos-related diseases
AU2014904751A0 (en)	2014-12-11	Methods for the treatment and prevention of asbestos-related diseases
AP2016009662A0 (en)	2016-12-31	Combination of taurine and racemethionine for treatment of liver diseases